Optimizing the timing of chemotherapy for mobilizing autologous blood hematopoietic progenitor cells

Transfusion

Volumn 47, Issue 4, 2007, Pages 629-635

  Hicks, Michelle L ^a   Lonial, Sagar ^a   Langston, Amelia ^a   Flowers, Christopher ^a   Roback, John D ^a   Smith, Kenneth J ^a   Mossavi Sai, Sarah ^a   Teagarden, Diane ^a   Hamilton, Ellie S ^a   Waller, Edmund K ^a,b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOKINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IFOSFAMIDE; MESNA; NAVELBINE; PACLITAXEL; PREDNISONE; RITUXIMAB; THALIDOMIDE; VINCRISTINE;

ADULT; AGED; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CD34 SELECTION; CLINICAL ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG DOSE REGIMEN; FEMALE; HODGKIN DISEASE; HUMAN; LEARNING ALGORITHM; MALE; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; REVIEW; STEM CELL MOBILIZATION; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; ALGORITHMS; ANTIGENS, CD34; BLOOD COMPONENT REMOVAL; COHORT STUDIES; CYCLOPHOSPHAMIDE; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HODGKIN DISEASE; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; MULTIPLE MYELOMA; TIME FACTORS;

EID: 33947375489     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2007.01164.x     Document Type: Review

References (19)

1. Appelbaum FR. Marrow transplantation for hematologic malignancies: a brief review of current status and future prospects. Semin Hematol 1988;25(3 Suppl 3):16-22.
2. Lonial S, Jones TW, Devine S, et al. High dose chemotherapy without hematopoietic cell support for the treatment of refractory lymphoma. Leuk Lymphoma 2000;36:497-502.
3. Lonial S, Hicks M, Rosenthal H, et al. A randomized trial comparing the combination of granulocyte-macrophage colony-stimulating factor plus granulocyte colony-stimulating factor versus granulocyte colony-stimulating factor for mobilization of dendritic cell subsets in hematopoietic progenitor cell products. Biol Blood Marrow Transplant 2004;10:848-57.
4. Ford CD, Chan KJ, Reilly WF, Petersen FB. An evaluation of predictive factors for CD34+ cell harvest yields from patients mobilized with chemotherapy and growth factors. Transfusion 2003;43:622-5.
5. Passos-Coelho JL, Braine HG, Davis JM, et al. Predictive factors for peripheral-blood progenitor-cell collections using a single large-volume leukapheresis after cyclophosphamide and granulocyte-macrophage colony-stimulating factor mobilization. J Clin Oncol 1995;13:705-14.
6. Trickett AE, Smith S, Kwan YL. Accurate calculation of blood volume to be processed by apheresis to achieve target CD34+ cell numbers for PBPC transplantation. Cytotherapy 2001;3:5-10.
7. Noga SJ, Vogelsang GB, Miller SC, et al. Using point-of-care CD34 enumeration to optimize PBSC collection conditions. Cytotherapy 2001;3:11-8.
8. Shpall EJ, Champlin R, Glaspy JA. Effect of CD34+ peripheral blood progenitor cell dose on hematopoietic recovery. Biol Blood Marrow Transplant 1998;4:84-92.
9. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235-42.
10. Moskowitz CH, Nimer SD, Classman JR, et al. The International Prognostic Index predicts for outcome following autologous stem cell transplantation in patients with relapsed and primary refractory intermediate-grade lymphoma. Bone Marrow Transplant 1999;23:561-7.
11. Arellano M, Lonial S, Hutcherson D, et al. Results of a clinical phase I dose-escalation study of cytarabine in combination with fixed-dose vinorelbine, paclitaxel, etoposide, and cisplatin for the treatment of relapsed/refractory lymphoma. Leuk Lymphoma 2006;47:2155-62.
12. Cortes J, Fayad L, O'Brien S, Keating M, Kantarjian H. Persistence of peripheral blood and bone marrow blasts during remission induction in adult acute lymphoblastic leukemia confers a poor prognosis depending on treatment intensity. Clin Cancer Res 1999;5:2491-7.
13. Lee CK, Barlogie B, Munshi N, et al. DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma. J Clin Oncol 2003;21:2732-9.
14. Barnett D, Janossy G, Lubenko A, et al. Guideline for the flow cytometric enumeration of CD34+ haematopoietic stem cells. Prepared by the CD34+ haematopoietic stem cellWorking Party. General Haematology Task Force of the British Committee for Standards in Haematology. Clin Lab Haematol 1999;21:301-8.
15. Kroschinsky F, Hölig K, Platzbecker U, et al. Efficacy of single-dose pegfilgrastim after chemotherapy for the mobilization of autologous peripheral blood stem cells in patients with malignant lymphoma or multiple myeloma. Transfusion 2006;46:1417-23.
16. Nosari A, Cairoli R, Ciapanna D, et al. Efficacy of single dose pegfilgrastim in enhancing the mobilization of CD34+ peripheral blood stem cells in aggressive lymphoma patients treated with cisplatin-aracytin-containing regimens. Bone Marrow Transplant 2006;38:413-6.
17. Pettengell R, Morgenstern GR, Woll PJ, et al. Peripheral blood progenitor cell transplantation in lymphoma and leukemia using a single apheresis. Blood 1993;82:3770-7.
18. Weaver CH, Schulman KA, Wilson-Relyea B, et al. Randomized trial of filgrastim, sargramostim, or sequential sargramostim and filgrastim after myelosuppressive chemotherapy for the harvesting of peripheral-blood stem cells. J Clin Oncol 2000;18:43-53.
19. Flomenberg N, Devine SM, Dipersiio JF. The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone. Blood 2005;106:1867-74.